We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05434585
Recruitment Status : Active, not recruiting
First Posted : June 28, 2022
Last Update Posted : February 8, 2023
Information provided by (Responsible Party):
Suzhou Abogen Biosciences Co., Ltd.

Brief Summary:
A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection. this study is conducted during Indonesian subjects aged 18 years and older who have not received SARS-CoV-2 vaccines.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: ABO1009-DP Biological: ABO-CoV.617.2 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 60 subjects will be randomized in a 2:2:1 ratio to receive ABO1009-DP, ABO-CoV.617.2, or placebo
Masking: Double (Participant, Investigator)
Masking Description: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
Actual Study Start Date : July 8, 2022
Actual Primary Completion Date : October 10, 2022
Estimated Study Completion Date : August 30, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Test group 1: ABO1009-DP
Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
Biological: ABO1009-DP

Experimental: Test group 2: ABO-CoV.617.2
Intramuscularly injecting 15 μg of ABO-CoV.617.2 into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
Biological: ABO-CoV.617.2

Placebo Comparator: Control group: Placebo
Intramuscularly injecting placebo into lateral deltoid of the upper arm of subjects on D0 and D28, respectively
Other: Placebo

Primary Outcome Measures :
  1. Incidence of solicited adverse events (AEs) [ Time Frame: 0 to 7 days after each injection ]
    Solicited adverse events 0 to 7 days after each injection;

  2. Incidence of unsolicited AEs [ Time Frame: 0 to 28 days after each injection ]
    Unsolicited adverse events 0 to 28 days after each injection ; Adverse reactions/events related to blood chemistry, blood routine, blood coagulation function and urinalysis indicators 4 days after each injection

  3. Changes of blood chemistry, blood routine, blood coagulation function and urinalysis indicators 4 days after each injection in comparison to pre-injection [ Time Frame: 4 days after each injection in comparison to pre-injection ]
    Adverse reactions/events related to blood chemistry, blood routine, blood coagulation function and urinalysis indicators 4 days after each injection

Secondary Outcome Measures :
  1. Level of S-RBD-specific IgG antibody, titer of neutralizing antibodies, and the number of T cells [ Time Frame: from the first vaccination to 12 months after 2 injections ]
    Evaluate the immunogenicity of ABO1009-DP and ABO-CoV.617.2 against SARS-CoV-2 (original strain, Delta variant and Omicron variant)

  2. Collection of Safety information [ Time Frame: through 12 months after 2 injections ]
    Serious adverse events (SAEs), adverse events of special interest (AESIs) and other medically attended adverse events (MAAEs) through 12 months after 2 injections

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Voluntarily sign the ICF approved by the Ethics Committee before any study procedure and agree to participate in the study.
  2. Healthy male or female able to provide legal identity certificate and aged 18 years and older when signing the ICF.
  3. Have not previously received any SARS-CoV-2 vaccine (marketed or investigational) before screening.
  4. Be able to communicate well with the investigator, and to understand and comply with the requirements of this clinical trial.
  5. Males or females of childbearing potential voluntarily take effective contraceptive methods from signing ICF to 3 months after the last vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device [IUD], condoms [male], diaphragm, and cervical cap).

Exclusion Criteria:

Exclusion criteria for the first dose

Subjects should not participate in this clinical study if any of the following criteria is met:

1. Subjects who do not meet health standard upon comprehensive physical examination, mainly including:

  1. Abnormal vital signs (pulse < 60 bpm or > 100 bpm, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg when keeping awake) with clinical significance.
  2. Body mass index (BMI) < 18 kg/m2 or > 30 kg/m2.
  3. Abnormal laboratory values and with clinical significance at the investigator's discretion at screening.
  4. Subjects who do not remain overall healthy (i.e., is anticipated to have fatal outcome of uncontrolled diseases within 12 months and is not able to provide blood as specified by the trial with anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination.

2. SARS-CoV-2 specific antibody positive at screening. 3. Positive SARS-CoV-2 RT-PCR result at screening. 4. Prior medical history of SARS-CoV-2, severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS), or other human coronavirus infections or diseases.

5. Fever (axillary temperature ≥ 37.3℃) on the day of vaccination with this study vaccine or within recent 72 hours.

6. Pregnant or lactating women, or those who plan to donate sperm or egg during the trial.

7. Prior history of allergic reaction or anaphylaxis to any vaccine or its excipients, e.g., hypersensitivity, urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc.

8. Prior use of any vaccine within 28 days before using this study vaccine or planning to use any vaccine other than this study vaccine during the study period.

Note: The exception is that licensed influenza vaccines can be received more than 28 days after the second dose of study injection.

9. Participation in the studies of any other interventional device or drug within 30 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug.

10. Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or platelet disorder), or a history of serious bleeding, or a history of massive bleeding after intramuscular injection or intravenous puncture or ecchymosis.

11. Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer (except skin basal cell carcinoma), congenital or acquired immunodeficiency (e.g., infection with human immunodeficiency virus [HIV]), uncontrolled autoimmune disease.

12. Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders, etc. influencing study results evaluation at the investigator's discretion.

13. Asplenia or functional asplenia. 14. Long-term use (continuous use ≥ 14 days) of immunosuppressants or other immunomodulators (e.g., glucocorticoids: prednisone or similar drugs) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants or nasal sprays). And the topical medications should not exceed the recommended dose in the labels for use or induce any signs of systemic exposure.

15. Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine.

16. Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject's compliance at the investigator's discretion.

17. Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits.

18. Receiving antituberculosis treatment. 19. Staff of test site, sponsor and contract research organization (CRO) taking part in the study.

Exclusion Criteria for the second dose

If the subjects have any of the followings prior to the second dose, vaccination will be terminated. However, other study procedures can be continued at the discretion of the investigators:

  1. Positive pregnancy test for female subjects of childbearing potential.
  2. Positive SARS-CoV-2 RT-PCR result.
  3. Serious hypersensitivity or serious adverse event causally related to vaccination has occurred following the first dose.
  4. Other circumstances considered by the investigator as inappropriate to receive the second dose of the vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05434585

Layout table for location information
Dr. Cipto Mangunkusumo Hospital
Jakarta, Indonesia
Persahabatan Hospital
Jakarta, Indonesia
Sponsors and Collaborators
Suzhou Abogen Biosciences Co., Ltd.
Layout table for investigator information
Study Director: Dingfeng Wu Suzhou Abogen Biosciences Co., Ltd.
Layout table for additonal information
Responsible Party: Suzhou Abogen Biosciences Co., Ltd.
ClinicalTrials.gov Identifier: NCT05434585    
Other Study ID Numbers: ABO1009-CoV.617.2-101Indonesia
First Posted: June 28, 2022    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Suzhou Abogen Biosciences Co., Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases